A male and female couple in their 60s hugging by the sea

Transforming access to esophageal care

We are a leading gastrointestinal health company delivering minimally invasive diagnostics for everyone, everywhere.
Explore
Impact

Earlier matters

Esophageal cancer is one of the fastest-growing cancers. Barrett's Esophagus is the only known precursor to Esophageal Adenocarcinoma, yet fewer than 10% of patients have a prior diagnosis.
Only

1 in 5

people with esophageal
cancer survive their diagnosis
A photo of the EndoSign cell collection device
EndoSign® is a fast and simple test to protect oesophageal health by detecting and monitoring for signs of pre-cancer and other diseases.
Learn more about our advanced molecular diagnostics:

Recent news

View All
05
December 2025
Cytoprime2 Study Proves Effectiveness of EndoSign® Capsule Sponge Test in Community Care for Early Detection of Esophageal Cancer
Read more
No items found.
30
August 2025
Cyted Health Secures $44 Million in Series B Financing to Accelerate US Expansion
Read more
No items found.
27
May 2025
Cyted Health Expands Clinical Advisory Board to Advance US Growth
Read more
No items found.